FY2025 EPS Estimates for OmniAb Decreased by Leerink Partnrs

OmniAb, Inc. (NASDAQ:OABI) – Equities research analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for OmniAb in a report released on Tuesday, March 18th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.64) per share for the year, down from their prior forecast of ($0.63). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb’s Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.61) EPS.

Several other research firms have also recently weighed in on OABI. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Wednesday. Benchmark dropped their price target on OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday.

OmniAb Trading Down 10.6 %

Shares of OABI stock opened at $2.27 on Friday. The stock has a market cap of $320.56 million, a P/E ratio of -3.66 and a beta of -0.14. The stock has a 50 day simple moving average of $3.36 and a 200 day simple moving average of $3.78. OmniAb has a 1 year low of $2.23 and a 1 year high of $5.72.

OmniAb (NASDAQ:OABI) last posted its earnings results on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.13 million. During the same quarter in the prior year, the business earned ($0.14) earnings per share.

Hedge Funds Weigh In On OmniAb

A number of institutional investors and hedge funds have recently made changes to their positions in OABI. Squarepoint Ops LLC lifted its position in OmniAb by 33.3% in the 4th quarter. Squarepoint Ops LLC now owns 39,264 shares of the company’s stock valued at $139,000 after acquiring an additional 9,809 shares in the last quarter. Sherbrooke Park Advisers LLC lifted its position in shares of OmniAb by 53.5% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock worth $61,000 after buying an additional 6,001 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of OmniAb by 29.9% during the 4th quarter. ProShare Advisors LLC now owns 31,724 shares of the company’s stock worth $112,000 after buying an additional 7,302 shares in the last quarter. Northeast Financial Consultants Inc purchased a new stake in shares of OmniAb during the 4th quarter worth approximately $393,000. Finally, Millennium Management LLC increased its stake in shares of OmniAb by 49.7% during the 4th quarter. Millennium Management LLC now owns 186,745 shares of the company’s stock worth $661,000 after purchasing an additional 61,993 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

Insider Activity at OmniAb

In other OmniAb news, Director John L. Higgins purchased 125,750 shares of the firm’s stock in a transaction on Thursday, March 20th. The stock was purchased at an average cost of $2.35 per share, for a total transaction of $295,512.50. Following the acquisition, the director now owns 2,762,887 shares in the company, valued at approximately $6,492,784.45. The trade was a 4.77 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Charles S. Berkman sold 25,489 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the sale, the insider now owns 343,190 shares of the company’s stock, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 112,260 shares of company stock worth $376,601 over the last three months. Company insiders own 8.60% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.